Characteristics and Long-Term Outcomes of Asymptomatic Patients with Hypertrophic Cardiomyopathy

Presenter:   Milind Desai 

This cohort study explored the long-term outcomes in asymptomatic hypertrophic cardiomyopathy (HCM) patients (NYHA Class I, N= 4,216) from 2002–2018, 40% of these patients had significant left ventricular outflow tract obstruction (LVOTO).

Obstructive HCM patients were older, more often female, and had greater cardiac structural abnormalities. Over a mean 11-year follow-up, obstructive HCM was associated with worse survival (20-year survival: 47%) compared to nonobstructive HCM (53%), which closely matched age-sex controls. Mortality was the primary outcome, with 36% deaths overall. These findings highlight the prognostic importance of dynamic LVOTO in asymptomatic HCM and support early identification and tailored intervention strategies to optimize long-term outcomes.

The Optimal Cut-Off and Integrative Risk Score for Incident Heart Failure by Nt-proBNP Among Pre-HF (stages A and B) Type 2 Diabetes Population - the DM-Heart Study

Presenter: Chung-Lieh Hung

The DM-Heart Study evaluated the predictive value of a risk prediction model incorporating Nt-proBNP and ten clinical variables to assess heart failure (HF) risk in 5,544 type 2 diabetes (T2D) patients in pre-HF stages (A/B), with validation in 1,325 patients.

Nt-proBNP was the strongest predictor, with an optimal cut-off of 77.3 pg/ml. The model showed strong discrimination (C-statistics: 0.751 derivation, 0.712 validation), and HF incidence increased stepwise across score categories; <10, 10-19, 20-29, 30-39, and ≥40 points. Kaplan-Meier analysis confirmed significant stratification. Findings support annual Nt-proBNP screening in T2D patients, as even low levels independently predict HF, enabling early risk identification and potential preventive intervention.

Global, Regional, and National Burden of Heart Failure in Young Adults Aged 15-49 Years, 1990-2021: Results from the Global Burden of Disease Study 2021

Presenter: Anran Xin

The temporal trends, geographical distribution, and demographic patterns of heart failure (HF) burden among young adults aged 15-49 years from 1990 to 2021 were determined to get evidence-based insights to apprise targeted prevention control strategies.

From 1990 to 2021, HF prevalence among young adults aged 15–49 years increased globally, rising from 147.1 to 178.5 cases per 100,000. Data from the Global Burden of Disease Study revealed significant growth across all socio-demographic index (SDI) regions, with low-SDI areas showing the highest percentage increases. High-income North America had the greatest prevalence, while East Asia and China exhibited the fastest growth rates. Cardiomyopathy was the leading cause, followed by ischemic and hypertensive heart disease. The weak correlation between SDI and HF burden highlights widespread disparities, emphasizing the need for region-specific prevention strategies targeting younger populations.

Rare and Common Variant Drivers of Ischemic Cardiomyopathy

Presenter: Kelvin Supriami

This study investigated whether genetic predisposition to dilated cardiomyopathy (DCM) would influence the development of ischemic cardiomyopathy (ICM) in coronary artery disease (CAD) patients.

Using data from UK Biobank, MGBB, and All of Us, researchers analyzed rare DCM variants and polygenic risk scores (PRS). Both were significantly associated with increased ICM risk (OR 3.28 for rare variants; OR 1.68 for high PRS). Among CAD patients, carriers of DCM variants and those with high PRS showed elevated risk of left ventricular dysfunction. Cardiac MRI revealed reduced ejection fraction in TTN variant carriers and high PRS individuals, suggesting genetic factors contribute to ICM progression.

Temporal Trends in Fatal and Non-Fatal Heart Failure Admissions in Denmark from 1996 to 2022: A 25-Year Analysis of >180.000 Patients with Incident Heart Failure

Presenter: Caroline Hartwell Garred

The nationwide Danish study ascertained the temporal trends in the risk of fatal and non-fatal HF admissions in 187,359 heart failure (HF) patients from 1996 to 2022.

The overall 5-year HF admission risk remained stable (28.9% vs 26.6%; HR: 0.93). The 5-year risk of fatal HF admissions declined significantly from 6.6% to 3.8% (HR: 0.60), while non-fatal HF admission rates remained stable (25.0% vs. 24.5%; HR: 0.97). Overall, the HF admission risk decreased modestly (HR: 0.93). Use of evidence-based therapies—ACEI/ARB/ARNI, beta-blockers, MRAs, and SGLT2i—increased substantially over time. Despite reduced fatal and overall heart failure admissions, non-fatal rates stayed constant, complicating real-world evaluation.

Ref: ESC Congress 2025, 29^thAug- 1^st Sept 2025, Madrid, Spain